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the difference between baseline HBV DNA and HBV 
DNA at HBVr (defined by authors) ranged between 1.9 
logs to 4.1 logs. Clinical significant outcomes were 
observed in those with difference around or above 3 
logs. In those with undetectable baseline HBV DNA, 
clinical significant outcomes were observed in those 
with HBV DNA above 6 logs at HBVr. Baseline HBV 
DNA level did not seem to be correlated with HBVr 
and clinical significant outcome due to HBVr.
Conclusion: Clinical significant outcomes due to HBVr 
seemed to be predicted by a more than 3 logs increase 
in HBV DNA from baseline and a level of more than 6 
logs HBV DNA when baseline HBV DNA level 
undetectable. A proper nomenclature of HBVr is 
needed to be able to predict the clinically significant 
outcomes due to HBVr.
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AVERTING AN EMERGING EPIDEMIC 
OF INCIDENT HEPATITIS C VIRUS 
INFECTION IN RAJSHAHI CITY OF 
BANGLADESH: MASSIVE
INTERVENTIONS NEEDED FOR 
INJECTING DRUG USERS (IDUs) IN 
BANGLADESH
Kalam M1
1Siam Health Care, Dhaka, Bangladesh
Background: IDUs in Bangladesh are a high-risk group 
for Hepatitis C Virus Infection due to lack of 
knowledge and risky behavior, and has led to the 
emerging epidemic of incident hepatitis C virus (HCV) 
infection across the border city of Rajshahi. We aim to 
examine the prevalence of HCV screening, 
confirmatory testing, and care experiences among 
young adult users in Rajshahi City of Bangladesh.
Materials & Methods: Two hundred young adults 
aged 18-29 years reporting past-month injected drug 
users were recruited into The Rajshahi City young 
adult drug study conducted between January 2016 
and December 2016. We used Pearson x2 test to
examine bivariate associations of self-reported HCV 
screening history in this cohort, and used modified 
Poisson regression to identify associated socio­
demographic and drug use patterns.
Results: Among 196 eligible participants, 154 (78.6%) 
reported prior screening for HCV, among whom 18 
(11.7%) reported positive results. Of these 18 
participants, 13 (72.2%) reported receiving a
confirmatory HCV test; 12 (66.7%) were referred for 
specialty HCV care. HCV screening was associated 
with injection drug use (adjusted prevalence ratio 
(APR): 1.19; 95% confidence interval (CI): 1.05-1.33) 
and history of hospitalization for psychiatric illness 
(APR: 1.23; 95% CI: 1.09-1.39). Younger participants 
(18-23 years) were less likely to have received 
screening (APR: 0.69; 95% CI: 0.57-0.85).
Conclusion: Although 3 in 4 young adults injecting 
drug users (IDUs) had been screened for HCV, post­
screening diagnostic testing, support, and referral to 
care were inadequate. Strategies may be needed to 
promote HCV screening, confirmatory diagnostic 
testing, and care leading to cure, early in the course of 
illicit drug use among young persons. IDUs in 
Bangladesh are a high-risk group for HCV due to lack 
of knowledge and risky behavior.
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Influence of the TLR4, TLR7
polymorphisms on the fibrosis
progression and DAAs efficacy in 
HCV/HIV- co-infected patients in 
Ukraine
KyrychenkoT1,2, Koval T2, Dubynska G2, Loban G2, Kaidashev I2
1Poltava Regional HIV/AIDS Prevention and Control Center, Poltava, 
Ukraine, 2Higher Medical Educational Institute o f  Ukraine "Ukrainian 
Medical Stomatological Academy", Poltava, Ukraine
Background: Recent studies have shown that TLR4 
Asp299Gly single-nucleotide polymorphisms (SNP) 
impacts the development of liver cirrhosis and the 
efficiency of peg-interferon based antiviral therapy in
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patients with hepatitis C virus (HCV) infection. Direct- 
acting antiviral drugs (DAAs) have a very high efficacy 
in HCV-infected persons. Impact of polymorphisms in 
TLR4 and TLR7 genes on DAAs effectiveness in 
HCV/HIV- coinfected patients seems to be unclear.
Materials & Methods: The retrospective
observational study included 106 HCV/HIV­
coinfected adult patients on ART > 6 months 
(TDF/3TC(FTC)/EFV 300/200/600 mg /day) who were 
assessed for the presence of SNP in TLR4 and TLR7 
genes. Toll-like receptors genotyping was performed 
by real-time polymerase chain reaction. Regimen 
choice of DAAs was based on viral genotype and stage 
of disease, according to guidelines. Negative HCV RNA 
at week 12 of post-treatment follow up was 
considered as sustained virological response (SVR). 
Potential risk factors associated with advanced liver 
fibrosis (F3-F4) and virological failure of DAAs were 
identified by using multivariable logistic regression 
models. SPSS version 22.0 was used for statistical 
analysis.
Results: The risk for accelerated fibrosis progression 
was significantly higher in patients with Asp299Gly 
TLR4 gene polymorphism (AOR=3,44; 95% CI [1,14­
11,67]) and wild genotype Gln11Gln TLR7 gene 
(AOR=1,6; 95% CI [1,11-3,7]) adjusted for age, sex and 
CD4+ count at the ART initiation.
Direct-acting antiviral therapy administered to HIV- 
patients with Asp299Gly TLR4 gene polymorphism has 
shown virological efficacy on the level of the patients 
with Asp/Asp TLR4 genotype (83,3% versus 86,3%).
Conclusion: This study suggests association between 
the presence of Asp299Gly TLR4 polymorphism, wild 
genotype of Gln11Gln TLR7 gene and accelerated 
fibrosis progression. In HIV/HCV- coinfected patients 
no significant association was found between genetic 
variation of the TLR4 and SVR of DAAs.
HIV Testing in patients presenting 
with Hepatitis C Monoinfection
Hanina S1, W ang S1, Nelson M1
1Chelsea A n d  Westminster Hospital, London, London, United 
Kingdom
Hepatitis C virus and HIV co-infection is a major global 
public health concern. An estimated 2.3 million 
people living with HIV are co-infected with Hepatitis C 
virus worldwide [1]. Extrapolating from data from the 
UK Collaborative HIV cohort (UK CHIV) study in 2012, 
it is estimated that 9000 people in the UK are co­
infected with HIV and hepatitis C [2]. Co-infection 
complicates each disease. Co-infected patients have a 
significantly poorer prognosis than monoinfected 
patients with either disease. Untreated HIV in 
hepatitis C patients increases the chance of liver 
damage compared with those infected with Hepatitis 
C alone [1], and liver disease caused by hepatitis C is 
an important cause of death in HIV patients [3]. 
Diagnosing co-infection early in patients improves the 
chances of hepatitis C treatment success and reduces 
related morbidity and mortality [2]. Given that HIV 
and Hepatitis C share many of the same risk factors for 
acquisition, and having HIV increases the risk of 
acquiring hepatitis C infection, early identification of 
at risk groups is paramount. British HIV Association 
guidelines recommends that every patient presenting 
with a new hepatitis C diagnosis should also be offer 
HIV testing as soon as possible, even if they recently 
tested negative [4].
This audit set out to determine how many 
monoinfected Hepatitis C patients receiving antiviral 
treatment from April 2016 -  March 2017 at Chelsea 
and Westminster Hospital, which is a large tertiary 
hospital in West London specializing in HIV, were 
tested for HIV prior to starting anti-viral treatment. 
The total number of patients included in the audit was 
176. Results showed 39% of all patients had not been 
offered a HIV test at any point. The mean time of HIV 
testing prior to treatment was 21 months, with a 
median of 10 months and a range of 0 -  133 months. 
This audit has highlighted the low level of HIV testing 
in monoinfected Hepatitis C patients, despite 
adequate resources, guidelines and pathways
Abstract 36
Reviews in Antiviral Therapy & Infectious Diseases 2017_11
